熱門資訊> 正文
Tempus AI宣布与Biontech合作
2024-09-04 21:00
- Tempus AI (NASDAQ:TEM) announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX) which leverages Tempus' multimodal datasets in support of BioNTech’s next-generation oncology pipeline.
- Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline.
- Source: Press Release
More on BioNTech, Tempus AI, etc.
- Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
- BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
- BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
- Moderna, Pfizer updated mRNA COVID vaccines authorized by FDA
- Partial hold on BioNTech, MediLink cancer drug lifted by FDA
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
